---
figid: PMC8471358__nutrients-13-03202-g003a
figtitle: 'Ketogenic Diets in Pancreatic Cancer and Associated Cachexia: Cellular
  Mechanisms and Clinical Perspectives'
organisms:
- NA
pmcid: PMC8471358
filename: nutrients-13-03202-g003a.jpg
figlink: ''
number: F3a
caption: 'Pancreatic cancer cell metabolism during a normal carbohydrate-rich diet
  versus a ketogenic diet. (A) Cancer cells undergo various metabolic modifications
  to satisfy their energy needs. High levels of insulin and insulin-like growth factor-I
  levels (IGF) induce upregulation of insulin/IGF-1-dependent phosphatidylinositol
  3-kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) system and the Ras/Raf/Mitogen-activated
  protein kinase/ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) cascade.
  KRAS mutation affects glucose dependency. The expression of glucose transporter
  1 (GLUT1) is stimulated, increasing glucose uptake and glycolysis. Pyruvate kinase
  isoform M2 (PKM2) and lactate dehydrogenase (LDH) are over-expressed, so lactate
  levels increase. Hyperglycemia inhibits AMP-activated protein kinase (AMPK), which
  in term activates mTOR (B) KDs reduce circulating glucose, which halts glycolysis.
  Decreased blood glucose, insulin, and IGF-I levels inhibit the PI3K/Akt/mTOR pathway,
  and lactate production, therefore inducing selective starvation in cancer cells,
  and targeting proliferation and survival. Ketosis activates AMPK, which inhibits
  mTOR. Mitochondrial dysfunction and lack of the mitochondrial enzymes that metabolize
  ketone bodies (KBs) cause the mitochondria to decrease ATP production. Note: Upward
  red arrows mean upregulation; downward blue arrows mean downregulation.'
papertitle: 'Ketogenic Diets in Pancreatic Cancer and Associated Cachexia: Cellular
  Mechanisms and Clinical Perspectives.'
reftext: Natalia E. Cortez, et al. Nutrients. 2021 Sep;13(9):3202.
year: '2021'
doi: 10.3390/nu13093202
journal_title: Nutrients
journal_nlm_ta: Nutrients
publisher_name: MDPI
keywords: ketogenic diet | pancreatic cancer | cancer cachexia | pancreatic ductal
  adenocarcinoma | microbiome | ketone bodies | cell metabolism
automl_pathway: 0.9025503
figid_alias: PMC8471358__F3a
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC8471358__F3a
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8471358__nutrients-13-03202-g003a.html
  '@type': Dataset
  description: 'Pancreatic cancer cell metabolism during a normal carbohydrate-rich
    diet versus a ketogenic diet. (A) Cancer cells undergo various metabolic modifications
    to satisfy their energy needs. High levels of insulin and insulin-like growth
    factor-I levels (IGF) induce upregulation of insulin/IGF-1-dependent phosphatidylinositol
    3-kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) system and the Ras/Raf/Mitogen-activated
    protein kinase/ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) cascade.
    KRAS mutation affects glucose dependency. The expression of glucose transporter
    1 (GLUT1) is stimulated, increasing glucose uptake and glycolysis. Pyruvate kinase
    isoform M2 (PKM2) and lactate dehydrogenase (LDH) are over-expressed, so lactate
    levels increase. Hyperglycemia inhibits AMP-activated protein kinase (AMPK), which
    in term activates mTOR (B) KDs reduce circulating glucose, which halts glycolysis.
    Decreased blood glucose, insulin, and IGF-I levels inhibit the PI3K/Akt/mTOR pathway,
    and lactate production, therefore inducing selective starvation in cancer cells,
    and targeting proliferation and survival. Ketosis activates AMPK, which inhibits
    mTOR. Mitochondrial dysfunction and lack of the mitochondrial enzymes that metabolize
    ketone bodies (KBs) cause the mitochondria to decrease ATP production. Note: Upward
    red arrows mean upregulation; downward blue arrows mean downregulation.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Raf
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Mtor
  - Tor
  - IRSp53
  - IleRS
  - chico
  - Amph
  - ATPsynbeta
  - Atpalpha
  - Ldh
  - SNF4Agamma
  - AMPKalpha
  - Hk
  - Pfk
  - CG15812
  - Aldh-III
  - G6P
  - Pep
  - bgcn
  - Coa
  - CycE
  - cyc
  - Kg
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - IGF1
  - IGF1R
  - KRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - IARS1
  - IRS1
  - IRS2
  - IRS4
  - APRT
  - MFAP1
  - ATP8A2
  - LDHA
  - LDHB
  - LDHC
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - PFKL
  - PFKM
  - PFKP
  - PKM
  - PKLR
  - PAEP
  - PREP
  - PTPN22
---
